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istration of patients, the management of adverse events and the cost of medica-
tion. A 3.5% discount rate was used for the case of all outcomes. Monte Carlo
simulation was employed to construct the 95% uncertainty intervals (UI) and to
compute cost-effectiveness acceptability curve. RESULTS: The mean total QALYs
estimate in the Len/Dex armwas 2.95 (95%UI: 2.75-3.14) and 2.20 (95%UI: 1.99-2.40)
in the case of bortezomib, an incremental gain of 0.75 (95%UI: 0.47-1.02) QALYs. The
mean total therapy cost was estimated at €76,782 (95%UI: 75,689-€77,927) and
46.380€ (95%UI: 45,719€-47,000€) for Len/Dex and Bortezomib, respectively. For both
comparators, total therapy cost ismainly attributed tomedication. The cost per life
year gained was estimated at €35,081 (95%UI: €19,357-€73,180) and the cost per
QALY gained at €42,012 (95%UI: 29,445-64,217). The probability for Len/Dex to be a
cost-effective therapy option at a threshold three times the per capital income
(€60,000 per QALY), was higher than 95%. Results remained constant under several
one-way sensitivity analyses.CONCLUSIONS:Therefore therapywith combination
of Len/Dex appears to be a cost-effective choice compared with Bortezomib alone
for multiple myeloma patients in Greece.
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OBJECTIVES: Currently in Brazil, acromegaly patients who fail having biochemical
control with somatostatine analogues face an unmet need. This research aims to
assess the economic impact of introducing pegvisomant to treat patients under the
public health care systemperspective.METHODS:An economicmodel considering
patients treatedwith Pegvisomant (PtwP) andpatientswithout biochemical control
(PWoC) was developed by using the available literature and Brazilian public data-
bases to evaluate the frequency of the following outcomes: Life years gained (LY),
quality adjusted life years gained (QALYs), cases of diabetes mellitus (DM), high
blood pressure (HBP), myocardial infarctions (MI), joint replacement surgeries (JR)
and number of life years without DM, HBP or MI (YWoDHM). The model was com-
posed by a decision tree portion to evaluate “JR” or “no JR” heath states, fromwhich
one-year Markov cycles were initiated considering the following health states: No
morbidity; DM; HBP; MI; HBPDM; DMMI; HBPMI; HBPDMMI; death. Proba-
bility inputs would either follow general population data to estimate biochemical
control or active acromegaly data to depict treatment failure. The time horizonwas
defined as 37 years, lifetime for PWoC since diagnose. Probabilistic sensitivity anal-
ysis was performed byMonte Carlo simulation using 10.000 iterations. 5% discount
rates were applied to costs and benefits. Values were represented in 2010 USD.
RESULTS: The values for PtwP versus PWoC were: 152.382 versus 143.935 for LY;
116.201 versus 87.227 for QALYs; 2.738 versus 6.141 for DM cases; 5.247 versus 7.244
for HBP cases; 753 versus 778 for MI cases; 67 versus 327 for JR cases and 219.319
versus149.896 for YWoDHM. ICERs for LY and QALYs were USD305.078,60 and
USD89.068,00, respectively. CONCLUSIONS: Pegvisomant has an important role in
reducing premature deaths and morbidities such as DM, HBP, JR and MI to the
PWoC under the public heath perspective in Brazil. Real world data is necessary to
identify underlying costs for the studied population.
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OBJECTIVES: CML is a malignant orphan disease of the blood and bone marrow.
Imatinib 400mg (up to 800mg with inadequate responses) daily is currently recom-
mended for treatment of newly diagnosed patients or after failure with interfer-
on-. Dasatinib 100 mg daily has been shown to offer significant clinical efficacy in
patients failing imatinib. Its cost-effectiveness compared to imatinib 600/800 mg
has not been assessed in this patient group. METHODS: A partitioned survival/
costingmodel was developed to estimate the lifetime costs and benefits associated
with dasatinib and imatinib from a UK health service perspective using a lifetime
horizon and monthly cycles. Prognosis was assigned for dasatinib and imatinib
patients to each of five initial best clinical response categories at 12 months. Re-
sponse category specific survival was based on long-term data from IRIS clinical
trial and response rates froma phase III randomized study. Utility and resource use
data were taken from recent UK based studies and all unit/drug costs were taken
from appropriate national databases and discounted at 3.5%per annum. Probabi-
listic and deterministic sensitivity analyses were conducted to estimate the confi-
dence around the results. Outcomes are reported via incremental cost-effective-
ness ratios (ICERs); benefit is expressed as quality adjusted life years (QALYs).
RESULTS: Compared to imatinib, dasatinib offered an additional 3.53 QALYs but
incurred £90,800 of additional costs. The ICER was therefore £25,700/QALY gained.
At a threshold of £30,000/QALY gained, dasatinib had a 98.1% probability of being
cost-effective. Deterministic analysis showed that the model was sensitive to
changes in 12 month response probabilities and drug costs. The model was robust
to changes in adverse event rates/ costs, and to utility estimates. CONCLUSIONS:
Dasatinib has been shown to be clinically superior to imatinib in CML patients who
have failed imatinib treatment and is a cost-effective alternative to imatinib dose
escalation in this patient group.
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OBJECTIVES: CML is a malignant blood disease. Imatinib 400mg daily is currently
recommended in newly diagnosed CML patients. Compared to imatinib, dasatinib
100mg daily has been shown to offer significant improvements in clinical efficacy
but its cost-effectiveness compared to imatinib has not been assessed in this pa-
tient group. METHODS: A partitioned survival/costing model was developed to
estimate the lifetime costs and benefits associated with dasatinib and imatinib for
a UK health service perspective using a lifetime horizon and monthly cycles. Indi-
viduals could switch from first to second line treatment at 3, 12 or 18 months for
reasons of inadequate clinical response and monthly for all other reasons. Re-
sponse category specific survival was based on long-term data from IRIS clinical
trial and response rates from a recent network-meta-analysis. Utility and resource
use datawere taken fromUK based studies and all unit/drug costs were taken from
national databases and discounted at 3.5% per annum. Probabilistic and determin-
istic sensitivity analyses were conducted to estimate the confidence around the
results. Outcomes are reported via incremental cost-effectiveness ratios (ICERs),
benefit is expressed as quality adjusted life years (QALYs). RESULTS: Compared to
imatinib, dasatinib offered an additional 0.71 QALYs (95% CI -0.15, 1.68) but in-
curred £17,646 of additional costs (95%CI -£24,259, £57,947). The ICERwas therefore
£24,922/QALY gained. At a threshold of £30,000/QALY gained, dasatinib had a 62.6%
probability of being cost-effective. Deterministic analysis showed that the model
was sensitive to changes in the 12-month response probabilities and drug costs.
When trial observed dose intensities were used, the ICER was £13,400/QALY
gained. The model was robust to changes in adverse event rates/ costs, and utility
estimates. CONCLUSIONS: Dasatinib has been shown to be clinically superior to
imatinib in newly diagnosed CML patients and is a cost-effective alternative to
imatinib in this patient group.
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OBJECTIVES: This study reports dosing and refill compliance observed in goli-
mumab (GLM)-treated ankylosing spondylitis (AS) patients.METHODS: This retro-
spective analysis assessed GLM use in adult AS patients with2 GLM prescriptions
between April 24, 2009 and December 31, 2010;  1 AS diagnosis during the study
period; continuous activity in the Source® LX database (6 months before; 6
months after the index GLM prescription); and a 28-31 day GLM supply. Refill com-
pliance was defined as 1 week of the expected 28-31 day (d) interval. The percent
of compliant GLM refill intervals and the percent of patients demonstrating refill
compliance at the 6th GLM dose were assessed. Data were summarized with de-
scriptive statistics. RESULTS: A total of 99 AS patients and 559 GLM refill intervals
were studied. The sample was 53% male; mean age of 44 years with 72% bio-
experienced. A 50 mg GLM dose occurred in 99% of all fills. The mean  SD refill
interval for the populationwas 35.121.0 dwith amedian of 30 d. The refill interval
of bio-experienced patients (34.818.7 d; median 30 d) was similar to bio-naïve
patients (35.825.8 d; median 31 d). Refill compliance was observed in 79% of all
intervals. Refill compliance at the 6th GLM dose was achieved by 83% of patients
overall.CONCLUSIONS: In this retrospective administrative claims analysis, 99% of
GLM doses were 50 mg with approximately once monthly refill intervals. Overall
refill compliance was observed in nearly 80% of all GLM refills and in greater than
80% of AS patients at the sixth GLM dose. Median refill interval and refill compli-
ance appeared similar in bio-experienced and bio-naïve subgroups. Further study
of these trends using additional data sources are desired to substantiate these
preliminary findings.
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OBJECTIVES: To understand how patients perceived the relevance and ease of
understanding of the questions included in SAT questionnaire to reflect key pa-
tient-reported outcomes of NP treatments and to provide recommendations mod-
ifications based on patient clinician interviews.METHODS: Semi-structured inter-
views were conducted with clinicians and NP patients to inform on treatment
attributes and pain impacts. Patients were debriefed on the SAT, a 5-item scale
evaluating pain, activity level, quality of life (QL) and satisfaction with treatment
(recommend treatment and undergo treatment again). SAT has a recall period
reflecting back to initiation of treatment. The qualitative analysis software AT-
LAS.ti 5.0 was used to analyze patient transcripts. Changes to SAT underwent
debriefings. RESULTS: Three NP clinicians and 44 patients (20 painful diabetic neu-
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ropathy, 16 HIV-associated neuropathy and 8 post herpetic neuralgia) with amean
age of 60.3(12.3) years and an even gender distribution were interviewed. Patient
treatment experience ranged from anticonvulsants (73%), antidepressants (34%),
opioids (25%), to topical medications (41%). Pain descriptors and treatment attri-
butes were similar across the three NP groups. Pain relief was judged the most
important treatment attribute, followed by ability to do activities. Sleep improve-
ment was another important attribute. Activity limitations and QL were perceived
as too broad and unspecific, andwere split into 3 concepts each (self care, daily and
physical activities; sleep, emotions, and social function). A 7-day recall period was
introduced. The item stem and response options were made consistent, and a
baseline and follow-up questionnaires were developed (except for the satisfaction
items) to enable monitoring onset of treatment benefit and change over time.
CONCLUSIONS: The content validity of the revised SAT was improved by the qual-
itative research, and NP treatment benefits are reflected in amore consistent fash-
ion by the changes. Baseline and follow-up versions make assessments of change
over time possible.
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OBJECTIVES: The National Institutes of Health (NIH) roadmap project: Patient-
Reported OutcomesMeasurement Information System® (PROMIS®) has developed
a series of large calibrated item banks and a computer adaptive testing (CAT) sys-
tem, allowing for efficient and robust assessment of a wide range of health out-
comes. This study seeks to assess the performance of PROMIS-CAT by evaluating
the frequency and sequence of items administered in a clinical trial. METHODS:
This was a 13-week randomized, double-blind, placebo-controlled drug switch
study in fibromyalgia patients. PROMIS-CAT assessmentswere scheduled for three
study visits using AssessmentCenterSM (v.1.0 item banks with standard CAT pa-
rameters) for the four following domains: Fatigue; Physical Function (PF); Satisfac-
tionwithDiscretionary Social Activity (DSA); andWakeDisturbance (WD). PROMIS-
CAT administers those items which are most informative to assess individual
patients based on their prior responses and their latent trait score. Findings were
summarized via descriptive statistics.RESULTS:A total of 107 randomized patients
completed at least one PROMIS-CAT assessment. Each PROMIS-CAT instrument
was administered 256 times. Pooled analysis of all administrations determined the
following observations: 36 of 95 (38%) Fatigue items were administered (including
4-items administered 50% of the time). 30/124 (24%) PF items were administered
(3-items 50% of the time). All items from the DSA (12-items) and WD (16-items)
banks were administered (4-items 50% of the time each). There were 41 unique
item sequences for Fatigue, 48 for PF, 20 for DSA and 21 for WD. DSA andWD each
had one sequence of items that was used in over half of the assessments.
CONCLUSIONS: PROMIS-CAT administered a subset of items from the full item
banks which are most informative in assessing individual patients with fibromy-
algia. Fewer than half the items from the Fatigue and Physical Function item banks
were administered. DSAandWDhad all items administered and fewer unique item
sequences.
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OBJECTIVES: Peripheral Neuropathy (PN) is a key side effect of several MM thera-
pies, including bortezomib. PRO instruments, such as the FACT/GOG-Ntx (v4.0)
11-item ‘Additional Concerns’ scale, may be helpful for early identification of pa-
tients at risk or with subclinical evolving PN. This analysis evaluated its ability to
predict PN after examining correlations between patient-reported FACT/GOG-Ntx
and physician-documented clinical PN (NCI-CTCAE v3.0) using data from a phase 3
trial. METHODS: In the VISTA study, 682 untreated, transplant-ineligible MM pa-
tients (median age 71 years) received up to nine 6-week cycles of bortezomib-
melphalan-prednisone (VMP) orMP, and completed FACT/GOG-Ntx v4.0 each cycle
(day 1). Correlations between clinical PN and FACT/GOG-Ntx sensory subscale
(items 1-4) were determined using Pearson correlation coefficients. A logistic re-
gression model evaluated detection accuracy; receiver operating characteristic
(ROC) curve analyses were conducted based on logistic regression results for pre-
diction of clinical PN by FACT/GOG-Ntx sensory subscale at cycles 1-5. Area under
ROC curve (AUC) is ameasure of accuracy; AUC should be.50 for an instrument to
be useful. RESULTS: Pearson correlation coefficient was 0.43, 0.44, and 0.47 at cy-
cles 3, 4, and 5, respectively, indicating some association between FACT/GOG-Ntx
and clinical PN. Using ROC curve analysis for prediction of grade 1, 2, 3, and 4
PN, respectively, AUCs were: .52, .53, .57, and .63 at cycle 1; .63, .64, .63, and .85 at
cycle 2; and .71, .75, .76, and .96 at cycle 3. At cycle 4, AUCswere .77, .79, and .75, and
at cycle 5 were .78, .80, and .79 for grade 1, 2, and 3 PN, respectively.
CONCLUSIONS: FACT/GOG-Ntx sensory subscale demonstrated substantial pre-
dictive utility for early detection of clinical PN. FACT/GOG-Ntx could be a useful
PRO tool for early bortezomib-associated PN detection and management. Similar
analyses of additional phase 2 (SUMMIT) and 3 (APEX) studies are planned.
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OBJECTIVES: To examine patient perspectives on perceived value of medications
used in moderate-to-severe psoriasis in the United States.METHODS: Online sur-
veys and patient focus groups were conducted from a nationally representative
psoriasis patient panel was conducted in April 2010. Respondents, aged 18 years
old, were grouped as mild and moderate-to-severe psoriasis. Participants were
asked to rate PsO severity based on palm rule where one palm is considered as
covering 1% body surface area (BSA). Participants were also asked about time to
diagnosis, treatment history, monthly out-of-pocket treatment costs, and value of
treatments. RESULTS: Of the 1013 participants, 50% were male, and mean age was
49 years. Psoriasis disease severity was reported by 32% (n321) as mild and 68%
(n692) as moderate-to-severe. Annual household income ranging from $25-75K
was reported by 40% of participants. Over 70% had been diagnosed with psoriasis
for 5years. Among those currently receiving prescription or over-the-counter
psoriasis treatment (n795), approximately one-third (mild37%, moderate-se-
vere35%) reported very good/excellent value for their PsO treatment as compared
to good (33% and 31%, respectively), fair (24%, 27%), and poor (6%, 8%). Patients
receiving biologic or disease modifying anti-rheumatic drugs (DMARD) (47% and
52%, respectively) rated the value of their treatment as very good/excellent com-
pared to other treatments, including light therapy. Those with out-of-pocket costs
$50 (mild88%, moderate-severe71%) were more likely to perceive their treat-
ment is of very good/excellent value. CONCLUSIONS: The majority of participants
in this survey suffered from long-standing moderate-to-severe psoriasis. The ma-
jority of participants, with the exception of those using biologics or DMARDs, per-
ceived they weren’t receiving good value for their psoriasis treatments. Partici-
pants with out-of-pocket medication costs less than $50/month perceived higher
treatment value.
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OBJECTIVES: To examine characteristics of individuals with moderate-to-severe
psoriasis in a US nationally representative population. METHODS: A nationally
representative patient panel was surveyed in April 2010 to recruit adult (18 years
old) psoriasis patients of all severity levels. Participants were asked about severity
of disease, affected locations, time to diagnosis, and treatment history. Participants
rated disease severity based on “palm rule”, where the palm of the hand was used
to estimate 1% body surface area (BSA). RESULTS: A total of 1013 patients re-
sponded to the survey. Fifty percent were female, 32% (n321) had mild and 68%
(n692) hadmoderate-to-severe psoriasis. Patient ages in yearswere distributed as
follows: 30%  40; 45% 40-59 and 25%  60. Over 70% of both mild and moderate-
severe severity patients were diagnosed 5 years ago. Among the moderate-to-
severe group, the top three body locations affected were elbows and/or arms (70%),
scalp (69%), and knees and/or legs (64%). 68% (n471) characterized their psoriasis
asmoderate-to-severe at time of diagnosis and 78% (n540) asmoderate-to-severe
before starting current treatment. Using the rule of palm, 70% reported 3-10% BSA
at time of diagnosis, 72% before starting current treatment, and 45% currently.
Prescription topical and other topical treatmentsweremost commonly used (48.8%
and 32.4% respectively), followed by over-the-counter (OTC) medications (25%),
prescription oral (14.6%), 12.6% biologics, and phototherapy (7.4%). 20% of patients
(n139) reported as not currently treating their psoriasis. CONCLUSIONS: Psoriasis
is a chronic condition affecting all age groups. The majority of patients are being
diagnosed when the disease has progressed to moderate or severe stage. Individ-
uals try various treatments to manage their psoriasis ranging from OTC medica-
tions to biologic treatments. Patient education and awareness programs, and
shared-decision making aides may help with early diagnosis of psoriasis and en-
able optimal treatment.
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OBJECTIVES: To examine patient insights and perspectives among individuals
with psoriasis using novel multi-discriminate analysis (MDA). METHODS: Patient
focus groups and online surveys were conducted from a nationally representative
psoriasis patient panel from 2Q-4Q2010. Participantswere asked about treatments,
impact on daily life, accessibility and affordability, and knowledge about psoriasis.
Key audio excerpts from focus group transcripts were used for moment-to-mo-
ment analysis in an online survey of psoriasis patients 18 years old. Cluster
analysis was used to segment patients into mutually exclusive patient groups
based patient characteristics and preferences. MDA was performed to identify key
points of divergence in perspective/opinion on the focus group dialogue. RESULTS:
Of the 1013 respondents, 50% were female, 32% (n321) had mild and 68% (n692)
hadmoderate-to-severe psoriasis. Patient ages in yearswere distributed as follows:
30%  40; 45% 40-59 and 25%  60. Patient preference for biologic treatments for
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